New regimen of therapy in the treatment of Brucellosis

Comparison the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the tratment of human brucellosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138708191441N1

Enrollment

166

Registered

2008-12-07

Start date

2005-04-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis. Brucella mellitensis

Interventions

None listed

Eligibility

Sex/Gender

All

Age

14 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria;all uncomplicated adult patients with brucellosis (except peripheral arthritis,sacroiliitis,epididymoorchitis).Exclusion criteria: age of less than 14 years, spondylitis, neurobrucellosis, pregnancy and receiving antibiotics more than 2 days before enrollment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cure. Timepoint: After completion of therapy. Method of measurement: Improvement of all clinical symptoms and signs.	—

Secondary

Measure	Time frame
Failure of therapy. Timepoint: After completion of treatment. Method of measurement: Persistence of the clinical signs and symptoms of the disease after treatment.;Relapse. Timepoint: Every three months interval for 12 months after treatment. Method of measurement: Reapearance of the clinical symptoms and signs of brucellosis during follow up period with increasing of the titers of STA or 2ME or isolation of brucella from blood culture either in symptomatic or asymptomatic cases.;Adverse effects of the drugs. Timepoint: During the course of treatment. Method of measurement: Measurement of BUN, creatinin, audial complaints.	—

Measure

Time frame

Failure of therapy. Timepoint: After completion of treatment. Method of measurement: Persistence of the clinical signs and symptoms of the disease after treatment.;Relapse. Timepoint: Every three months interval for 12 months after treatment. Method of measurement: Reapearance of the clinical symptoms and signs of brucellosis during follow up period with increasing of the titers of STA or 2ME or isolation of brucella from blood culture either in symptomatic or asymptomatic cases.;Adverse effects of the drugs. Timepoint: During the course of treatment. Method of measurement: Measurement of BUN, creatinin, audial complaints.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Hasanjani Roushan

Yahyanejad Hospital, Babol Medical University

mr.roshan@mubabol.ac.ir+98 11 1222 3594

Outcome results